SCHEMBL3126751

SCHEMBL3126751

CCN1C(=O)/C(=C\c2ccc(-c3ccccc3Cl)o2)SC1=S

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 9/20 0.76
TNFRSF1A P19438 2/20 0.73
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
ALDH1A1 P00352 2/20 0.67
MAPT P10636 2/20 0.67
USP2 O75604 1/20 0.61
DNMT1 P26358 1/20 0.61
BLM P54132 1/20 0.61
STAT3 P40763 1/20 0.60
ENPP2 Q13822 1/20 0.60
INSR P06213 1/20 0.59
IGF1R P08069 1/20 0.59
LMNA P02545 1/20 0.58
POLB P06746 1/20 0.58
HPGD P15428 1/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
RECQL P46063 1/20 0.58
MCL1 Q07820 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3136515 1.00 MAP3K5 (0.76) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1
SCHEMBL3136503 1.00 MAP3K5 (0.76) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1
SCHEMBL3900346 0.93 MAP3K5 (0.78) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1
SCHEMBL3900350 0.93 MAP3K5 (0.78) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1
SCHEMBL13821857 0.92 TNFRSF1A (0.67) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1
SCHEMBL13813621 0.91 TNFRSF1A (0.66) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1
SCHEMBL3897831 0.88 MAP3K5 (0.78) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1
SCHEMBL3897828 0.88 MAP3K5 (0.78) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1
SCHEMBL3134456 0.88 TNFRSF1A (0.74) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1
SCHEMBL3134440 0.88 TNFRSF1A (0.74) MAP3K5TNFRSF1AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 US claimed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 WO claimed
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 US disclosed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses MAVS, LAMP1, HAVCR2 MAP3K5 3869/4885TNFRSF1A 2355/4885MEN1 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.